Back to discover

Protein / target

Glutamate-gated chloride channel subunit beta

P91730Haemonchus contortusSwiss-Prot
30
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Glutamate-gated chloride channel

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Glutamate-gated chloride channel subunit; channel properties may be modulated by the formation of heteromeric channels.

View complete UniProt function annotation

Glutamate-gated chloride channel subunit; channel properties may be modulated by the formation of heteromeric channels. Glutamate binding triggers a rapidly reversible current, while the anti-helmintic drug ivermectin triggers a permanently open channel configuration

Subcellular location

Postsynaptic cell membraneCell membrane
Domains and Gene Ontology detail (4)

Gene Ontology

  • Cchloride channel complex
  • Cpostsynaptic membrane
  • Fextracellularly glutamate-gated chloride channel activity
  • Ftransmembrane signaling receptor activity

432 aa · 50 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Chloride transportUniProt · GO
View supporting evidence

Chloride transport

  • ·Glutamate-gated chloride channel subunit; channel properties may be modulated by the for…
  • ·chloride channel complex
  • ·extracellularly glutamate-gated chloride channel activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Approved medicines with mapped indications

1 medicine · 3 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Helminthiasis1 medicine
Onchocerciasis1 medicine
Rosacea1 medicine

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

ivermectin
Narrow target profileModulator

Glutamate-gated chloride channel modulator

Indicated for Helminthiasis, Onchocerciasis, Rosacea

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

NOT_YET_RECRUITING · via ivermectin · NCT07487805

ACTIVE_NOT_RECRUITING · via ivermectin · NCT04108897

UNKNOWN · via ivermectin · NCT05605925

WITHDRAWN · via ivermectin · NCT04891250

COMPLETED · via ivermectin · NCT05085665

COMPLETED · via ivermectin · NCT04739410

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2026-04-07

    Approval: IVERMECTIN (ANDA218509)

    fda · regulatory · fda · via ivermectin

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.